- Respiratory therapeutics market valued at $30.1 billion in 2010
- Average cost of respiratory disorder treatment valued at $611 p/a
- Respiratory disorders include: allergic rhinitis, asthma, COPD and idiopathic pulmonary fibrosis
LONDON--(BUSINESS WIRE)-- The global market for respiratory therapeutics is anticipating growth of over 3% CAGR to 2017, at which point it is expected to be worth $37.4 billion, according to a new research report available from companiesandmarkets.com. Nearly 50 million incidences of respiratory disorders were recorded in 2010.
Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and Pirfenidone May Offset Negative Effect of Patent Expiries
The respiratory disorders therapeutics market will witness a decline in growth rates over the next few years, following patent expiries for a number of drugs and the subsequent entrance of generic competitors. By 2017 it is expected that branded medication will hold just 51% of the respiratory disorders treatment market.
Upcoming patent expiries of note include: Advair (fluticasone and salmeterol), Nasonex (mometasone furoate monohydrate), Rhinocort (budesonide), Symbicort (budesonide and formoterol inhalation), Singulair (montelukast) and Tracleer (bosentan).
Although growth in the respiratory therapeutics market will be subdued over the reporting period, it will be bolstered by the release of new treatments - Indacaterol, Riociguat (BAY 63-2521) and VX-770.
As competition intensifies, there will be an increase in the number of global mergers and acquisitions within the respiratory therapeutics industry, as companies tactically position themselves in prominent market positions. In 2011, we have seen the acquisition of Clinical Data by Forest Laboratories, in a deal worth $1,200 million. The majority of M&A transactions since 2004 have been valued at less than $200 million. During the reporting period the majority (45%) of consolidation activity involved companies in the US.
The September 2011 report provides a comprehensive overview of the respiratory therapeutic treatment market in Europe, Japan and the US. It includes analysis of the competitive landscape, key players and their products, treatment methods, and M&A activity. The treatments and therapy costs for the seven most prevalent respiratory disorders are analysed at length: asthma, COPD, pulmonary arterial hypertension, cystic fibrosis, allergic rhinitis, idiopathic pulmonary fibrosis and bronchitis.
Companies & Markets
London (UK): +44 (0) 203 086 8600
KEYWORDS: United Kingdom Europe
INDUSTRY KEYWORDS: Health Hospitals Medical Devices Other Health